AL
ALCJ.PA Crossject
- Market cap
- EUR 74.7M
- P/E
- -
- P/B
- 25.11x
- ROE
- -1,152.7%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALCJ.PA undervalued?
Graham numberThe Graham number of Crossject cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Crossject fundamental analysis
1 of 11 checks passedROE 2/2
The stock's ROE exceeds expectations (798.35%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.
ROA 0/2
The stock's ROA (-50.33%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 0/2
The stock's elevated P/BV ratio (59.41x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.
DER 0/2
The company has a high debt to equity ratio (592%), which means it owes a lot of money compared to what it actually owns, making it financially risky.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.
Assets Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Graham Number 0/1
Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.
Buffet Intrinsic Value 0/1
Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Crossject stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In additio…
Full company profileCrossject financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Crossject annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.42M | 3.23M | 2.44M | 500K | 4.84M | 912K | 954K | 145K | 4.12M | 0.00 | - |
| Gross Profit | -282K | 976K | -524K | -9.90M | 895K | -11.1M | -13.9M | -6.14M | -21.9M | -22.4M | -47.5M |
| Operating Income | -7.64M | -8.98M | -12.0M | -9.12M | -10.9M | -11.8M | -13.2M | -11.8M | -15.2M | -12.1M | -38.1M |
| EBITDA | -5.94M | -6.36M | -9.04M | -4.76M | -7.13M | -7.33M | -8.03M | -7.30M | -9.35M | -7.21M | -26.6M |
| Net Income | -6.66M | -7.61M | -10.7M | -7.17M | -9.84M | -10.8M | -11.2M | -8.64M | -12.8M | -10.4M | -34.3M |
| EPS | -0.91 | -0.85 | -0.79 | -0.36 | -0.41 | -0.42 | -0.31 | -0.23 | -0.28 | -0.20 | -0.57 |
| Balance Sheet | |||||||||||
| Total Assets | 14.2M | 17.7M | 20.2M | 24.5M | 33.6M | 31.5M | 32.9M | 28.6M | 31.6M | 30.4M | 35.6M |
| Total Liabilities | 7.97M | 11.6M | 18.5M | 21.5M | 34.7M | 37.0M | 30.2M | 33.9M | 34.2M | 35.3M | 32.6M |
| Shareholders' Equity | 6.28M | 6.09M | 1.65M | 3.01M | -1.13M | -6.15M | 2.02M | -5.27M | -2.67M | -4.87M | 2.98M |
| Cash & Short-term Investments | 2.63M | 2.81M | 4.82M | 7.91M | 8.28M | 9.98M | 7.77M | 2.30M | 7.04M | 5.08M | 12.3M |
| Total Debt | 755K | 2.35M | 12.0M | 10.5M | 21.1M | 24.3M | 14.1M | 19.0M | 18.4M | 19.8M | 18.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.40M | -4.97M | -8.02M | -5.51M | -5.46M | -6.08M | -5.08M | -6.20M | -7.96M | -6.35M | -7.78M |
| Capital Expenditure | 6.07M | 4.25M | 3.27M | 4.40M | 6.10M | 6.73M | 6.78M | 6.40M | 3.53M | 4.50M | 7.24M |
| Free Cash Flow | -10.5M | -9.22M | -11.3M | -9.91M | -11.6M | -12.8M | -11.9M | -12.6M | -11.5M | -10.8M | -15.0M |
| Ratios | |||||||||||
| ROE | -106.0% | -125.1% | -647.4% | -238.0% | - | - | -552.1% | - | - | - | -1,152.7% |
| ROA | -46.8% | -43.0% | -53.1% | -29.3% | -29.3% | -34.3% | -34.0% | -30.2% | -40.5% | -34.1% | -96.4% |
| Net Profit Margin | -468.3% | -235.3% | -438.3% | -1,434.7% | -203.2% | -1,184.9% | -1,169.5% | -5,957.2% | -310.9% | - | - |
| Debt to Equity | 0.12x | 0.39x | 7.22x | 3.48x | - | - | 6.99x | - | - | - | 6.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Crossject dividends
Crossject has not paid dividends in the last 9 fiscal years.
Last stock split: 518:509 on Jun 10, 2025.
Who owns Crossject
- Insiders 19.63%
- Institutions 0.40%
- Public & others 79.97%
- Shares outstanding 60.6M
- Free float 51.2M
Crossject company profile
- Company name
- Crossject
- Ticker
- ALCJ.PA
- ISIN
- FR0011716265
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 99
- Fiscal year end
- December
- Address
- 6 Rue Pauline Kergomard, Dijon, France, 21000
- Phone
- 33 3 80 54 98 50
- Website
- crossject.com
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Crossject management
6- Mr. Patrick AlexandreCo-Founder, CEO & Chairman of the Executive Board
- Mr. Lionel SeltzCO & Member of Executive Board
- Dr. Isabelle LiebschützChief Quality & Regulatory Officer and Member of Executive Board
- Dr. Olivier Lacombe PH.D.Pharmaceutical Development Director & Member of Executive Board
- Mr. Didier MorinIndustrial Director & Member of Executive Board
- Mr. Tony TiptonChief Operating Officer of U.S